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Fremont and San Diego, California; and Minneapolis, Minnesota
Objectives These studies describe molecular forms of circulating B-type natriuretic peptide (BNP) as well as their biological
activity.
Background Increased circulating levels of immunoreactive BNP correlate with the severity of heart failure and are consid-
ered a sensitive biomarker. However, little is known about the molecular forms of circulating BNP and their bio-
logical activity.
Methods Western blot analysis was used to characterize immunoreactive BNP species in heart failure plasma. Recombi-
nant proBNP was assessed for reactivity in commercially available BNP assays and cell activity by cyclic
guanosine monophosphate production in vascular cells.
Results Heart failure plasma contained both low- (LMW-BNP) and high-molecular-weight (HMW-BNP) forms. The LMW-
BNP migrated similarly to a 32-amino acid BNP standard, whereas HMW-BNP, when deglycosylated, was similar
to deglycosylated recombinant proBNP. Recombinant proBNP and BNP were equally recognized by the Triage
BNP assay (Biosite, San Diego, California). Furthermore, recombinant proBNP and BNP were both recognized by
the Advia Centaur BNP test (Bayer Diagnostics, Tarrytown, New York), but only recombinant proBNP was recog-
nized by the Elecsys NTproBNP assay (Roche Diagnostics, Indianapolis, Indiana). Recombinant proBNP exerted
significantly less biological activity than BNP on human endothelial and vascular smooth muscle cells. Compari-
son of effective concentration (50%) values indicates that proBNP is 6- to 8-fold less potent than BNP in these
human cells.
Conclusions This study demonstrates that proBNP, constituting a substantial portion of immunoreactive BNP in heart failure
plasma, possesses significantly lower biological activity than the processed 32-amino acid hormone. These re-
sults implicate a discordance in heart failure between the high circulating levels of immunoreactive BNP and
hormone activity, suggesting that some patients may be in a state of natriuretic peptide deficiency. (J Am Coll
Cardiol 2007;49:1071–8) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.063C
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mhe cardiac-derived hormones atrial natriuretic peptide
ANP) and B-type natriuretic peptide (BNP) play impor-
ant roles in the regulation of cardiovascular and renal
omeostasis (1). B-type natriuretic peptide is synthesized
See page 1089
s a 108-amino acid prohormone termed proBNP that is
roteolytically cleaved to release the 32-amino acid
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ccepted October 10, 2006.-terminal BNP peptide (Fig. 1) (2,3). Both of these forms
f BNP (proBNP and BNP) were purified and character-
zed by amino acid sequence analysis from BNP-containing
eptides isolated from human atrial extracts (4).
In clinical heart failure (HF) syndromes, cardiac BNP
xpression and secretion increases in response to hemody-
amic forces such as elevated filling pressure due to fluid
verload and increased afterload from the effects of neuro-
ormones angiotensin II and endothelin (5–8). Numerous
tudies have reported that increased circulating levels of
NP correlate with the severity of HF and that elevated
NP levels provide a sensitive biomarker for the diagnosis
nd prognosis of HF (9 –12). Although HF patients
requently have increased plasma concentrations of im-
unoreactive BNP (iBNP), they show a paradoxic lackf BNP activity with sodium and fluid retention associ-
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Functional Heterogeneity of Circulating BNP March 13, 2007:1071–8ated with activation of the renin-
angiotensin-aldosterone and en-
dothelin pathways (4,13). This
observation raises important
questions regarding the structure
and activity of circulating iBNP
in the HF state.
A number of reports describing
circulating iBNP have demon-
strated high-molecular-weight
material, presumably forms of
proBNP, as well as low-molecular-
weight material, presumably
forms of BNP (14,15). Using a
proBNP-specific immunoassay,
Giuliani et al. (16) reported sig-
nificant amounts of proBNP in
ealthy as well as HF individuals. Compared with iBNP,
roBNP was present at similar or greater amounts (16).
here is, in fact, little detectable 32-amino acid BNP
eptide by radioimmunoassay of fractionated plasma from
F patients (17). Consistent with these findings,
awkridge et al. (18), using mass spectroscopy techniques
o analyze plasma BNP from severe HF patients, failed to
etect the 32-amino acid peptide despite high levels of
BNP measured by the Triage point-of-care assay, indicat-
ng that altered forms of iBNP species existed in the plasma.
he precise structure of circulating BNP is not known.
etter characterization of the molecular forms of BNP
irculating in HF patients and the biological activities of
hese forms would provide important insights for our
nderstanding of the HF milieu that may have a profound
mpact on diagnosis, prognosis, and treatment of this
isease.
B-type natriuretic peptide exerts most if not all of its
iological activities via a membrane-bound guanylyl cyclase
eceptor termed natriuretic peptide receptor A (NPRA)
19). Binding of BNP to this receptor on endothelial cells
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
cGMP  cyclic guanosine
monophosphate
CHO  Chinese hamster
ovary
EC50  effective
concentration (50%)
HF  heart failure
HMW  high molecular
weight
NPRA  natriuretic peptide
receptor A
Figure 1 Processing of a 108-Amino Acid proBNP Into
an Active Form of C-Terminal 32-Amino Acid BNP
BNP  B-type natriuretic peptide.nnd vascular smooth muscle cells results in the cellular
ynthesis of cyclic guanosine monophosphate (cGMP),
hich mediates the vascular effects of this peptide (20–22).
We hypothesized that profiling the molecular species of
BNP in plasma from HF patients and determining the
elative biological activity of unprocessed proBNP and
rocessed BNP would advance our understanding of the
rue hormonal state of HF patients. Therefore, we studied
he physical forms of circulating immunoreactive BNP in
F using Western blot techniques and the biological
ctivity of recombinant forms of proBNP as determined by
timulation of cGMP production in cell culture assays. We
lso searched for evidence of peripheral activation of
roBNP and examined the specificity of various commercial
ssays for 32-amino acid BNP, N-terminal (NT) proBNP,
nd intact proBNP.
ethods
aterials. Human recombinant BNP was provided by Scios
Fremont, California). Recombinant NT-proBNP 1–76 was
urchased from Phoenix Pharmaceuticals (Belmont, Cali-
ornia). Complete Protease Inhibitor Cocktail was from Roche
pplied Science (Indianapolis, Indiana). Endo--N-
cetylgalactosaminidase, -3,6,8,9-neuraminidase, and
-1,2,3,4,6-N-acetyl-glucoseaminidase were obtained from
MD Biosciences (San Diego, California). -(1¡4)-
alactosidase was obtained from Sigma (St. Louis, Missouri).
xpression and purification of proBNP in CHO cells
nd E. coli. Expression and purification of recombinant
roBNP in Chinese hamster ovary (CHO) cells is described
n detail elsewhere (23). Briefly, a plasmid carrying the
enes for preproBNP and glutamine synthase was con-
tructed to transfect CHO cells. Stably transfected cell lines
ere generated by selection for resistance to methionine
ulfoximine. The level of secreted proBNP was determined
y sandwich ELISA using 2 monoclonal antibodies directed
gainst full-length BNP32 and the C-terminus (amino
cids 26 to 32) of BNP32, respectively. The most promising
ell line was expanded, and proBNP in the medium was
urified by antibody-affinity chromatography and further by
trong cation-exchange chromatography (23).
For expression of proBNP in Escherichia coli, the gene
ncoding a full length of proBNP (amino acids 1 to 108) was
loned into expression vector pET24 (EMD Biosciences). An
-terminal His6-tag and linker sequence, followed by an
TEV protease cleavage site was added to aid purification. The
ranslated protein therefore has the N-terminal sequence
HHHHHHNYNIPTTENLYFQG preceding proBNP
molecular weight 14,515.4 Da). Escherichia coli strain Ro-
etta DE3, pLysS (EMD Biosciences) was used for expres-
ion induced with IPTG. Soluble proBNP was purified by
mmobilized metal affinity chromatography followed by
trong cation-exchange chromatography to achieve the de-
ired purity. For the present studies, the purification tag was
ot removed.
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March 13, 2007:1071–8 Functional Heterogeneity of Circulating BNPProtein identity and concentration for both recombinant
roBNP proteins (derived from mammalian cells and bac-
eria) were determined by N-terminal sequencing and
mino acid analysis, respectively. In both cases, purity of the
nal product was 95% by sodium dodecyl sulfate poly-
crylamide gel electrophoresis (SDS-PAGE) analysis.
mmunoprecipitation and Western blot analysis. Plasma
amples from 5 consenting patients with New York Heart
ssociation functional class IV chronic HF were analyzed.
he protocol for collection of these samples was approved
y the Veterans Administration Medical Center Institu-
ional Review Board, San Diego, California. For immuno-
recipitation, a monoclonal antibody directed against
NP32 was cross-linked to POROS XL ID resin according
o the manufacturer’s instructions (Applied Biosystems,
oster City, California). The plasma (2.5 ml) was incubated
ith 3 l BNP antibody-conjugated beads for 16 hours at
°C. The immunoprecipitates were washed with phosphate-
uffered solution, then electrophoresed and transfered onto
VDF membrane for Western blotting. A monoclonal
ntibody directed against the C-terminus of BNP32 was
sed as the primary detection antibody, and bands were
isualized on film using ECL Advanced detection (GE
ealthcare, Piscataway, New Jersey).
eglycosylation of proBNP. ProBNP derived from CHO
nd the immunoprecipitates from HF patients were incubated
ith a deglycosylation enzyme cocktail consisting of endo--
-acetylgalactosaminidase, -3,6,8,9-neuraminidase, -1,
,3,4,6-N-acetyl-glucoseaminidase, and -(1¡4)-galac-
osidase in 50 mmol/l sodium phosphate buffer, pH 6.0 at
7°C for 8 hours. Reactions were stopped by addition of
DS-PAGE sample buffer and heating, then subjected to
estern blot analysis.
ell culture. Primary human aortic endothelial cells, pri-
ary human coronary artery endothelial cells, primary
uman umbilical endothelial cells, and primary human
ortic smooth muscle cells were purchased from Cambrex
Walkersville, Maryland). Cells at passages 3 through 5
ere grown in EGM-2 MV complete medium containing
% fetal bovine serum (FBS). After confluence, cells were
plit and cultured in 6-well plates for the experiments.
ecombinant expression of the biological receptor hu-
an NPRA in CHO cells. A 3.2-kb cDNA encoding the
ull length of human NPRA was subcloned into the Xba
/Sal I sites of plasmid pAXneoRX. The NPRA constructs
ere transfected into CHO-K1 cells. The transfected cells
ere selected for growth in the medium containing the
eomycin analog G418, and positive clones were screened
y determination of 125I-ANP binding and ANP-
timulated cyclic GMP accumulation. The CHO cells
tably overexpressing human NPRA were named CHO-
CA cells. Cells between passages 7 through 12 were
rown in medium containing 45% DMEM 21, 45% Coon’s
12, 10% FBS, 10 mmol/l HEPES, and 2 mmol/l
lutamine. tetermination of intracellular cGMP accumulation. Cells
ere changed to serum-free medium and preincubated with
.1 mmol/l 3-isobutyl-1-methylxanthine for 1 h, then
reated with varying concentrations of human BNP or
HO-derived human proBNP ranging from 0.1 nmol/l to
,000 nmol/l for 10 min. Cells were lysed with 0.1 mol/l
Cl at room temperature for 20 min. The lysates were
entrifuged at 600 g, and the levels of cGMP in the
upernatant were measured using a cGMP enzyme immu-
oassay kit from Assay Designs (Ann Arbor, Michigan).
easurement of BNP and proBNP by the Triage BNP
ssay, Advia Centaur BNP assay, and the Elecsys 2010
roBNP assay. Known amounts of BNP or proBNP were
dded to normal human plasma (obtained from VWR,
est Chester, Pennsylvania), and samples were measured
y the Triage BNP test (Biosite, San Diego, California),
dvia Centaur BNP test (Bayer Diagnostics, Tarrytown,
ew York), and the Elecsys 2010 NT-proBNP assay that
etermines NT-proBNP (Roche Diagnostics, Indianapolis,
ndiana) according to manufacturers’ instructions.
ata analysis. The data were analyzed and plotted using
raphPad Prism 4 software (GraphPad, San Diego, Cali-
ornia). Effective concentration (50%) (EC50) values were
alculated with Sigmoidal dose-response equation. Statisti-
al analysis was prepared using a t test with the Satter-
hwaite approximation for the degrees of freedom. A con-
matory Wilcoxon nonparametric test was also prepared.
ll calculations were prepared in SAS version 8 (SAS
nstitute, Cary, North Carolina).
esults
haracterization of circulating iBNP in patients with
dvanced HF demonstrated that proBNP is a major form
f immunoreactive BNP in HF plasma. Immunoreactive
NP species in HF plasma were evaluated by Western blot
nalysis using antibodies directed against BNP. The analysis
dentified high-molecular-weight (HMW) and low-
olecular-weight (LMW) BNP species (Fig. 2A). The
MW-BNP species migrated at an approximate molecular
eight range of 20 kDa to 22 kDa, and the recombinant
roBNP used as a standard had an estimated molecular
eight range of 22 kDa to 24 kDa. The LMW-BNP
pecies migrated in a manner similar to that of the 32-amino
cid species. In 4 of the 5 samples tested, the HMW-BNP
epresented a significant amount of the total immunoreac-
ive BNP material compared with the LMW-BNP.
The mobility of the HMW-BNP species was lower than
redicted for a 108-amino acid protein, suggesting the
rotein may be glycosylated, a typical post-translational
odification of plasma proteins. Structural characterization
f the mammalian cell-derived recombinant proBNP has
etermined that there are 7 sites of O-linked oligosaccha-
ide attachment within the propeptide region (23). There-
ore, deglycosylation of both the recombinant protein and
he immunoprecipitates from patients were performed to
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Functional Heterogeneity of Circulating BNP March 13, 2007:1071–8nzymatically remove O-linked oligosaccharides. Western
lot analysis (Fig. 2B) revealed a reduction in the molecular
eight of the HMW-BNP species present in patient plasma
o approximately 12 kDa, the predicted size of the 108-
mino acid form. The LMW-BNP species appeared unal-
ered. The deglycosylated HMW-BNP species comigrated
ith the deglycosylated CHO-derived proBNP, suggesting
hat the 2 species were similar. For this reason, differences in
igration of recombinant proBNP and HMW-BNP before
eglycosylation probably represent different patterns of gly-
osylation between the mammalian cells used for recombi-
ant expression (CHO) and humans.
These results suggest that HMW forms of BNP are
revalent in HF plasma. Furthermore, this immunoreactive
MW-BNP material is similar to proBNP, the 108-amino
cid unprocessed form of the hormone.
hysiologic assay of cGMP production demonstrated
arked limitation of cellular bioactivity of recombinant
roBNP. Because HMW material similar to proBNP ap-
ears to constitute a substantial portion of the immunore-
ctive BNP in HF plasma, we evaluated the stimulation of
GMP production as an index of the biological activity of
roBNP and BNP in primary human endothelial cells
repared from aorta, coronary artery, and umbilical vein as
ell as primary human aortic smooth muscle cells. Cells
ere treated with increasing concentrations of BNP or
roBNP for 10 min, and intracellular cGMP levels were
etermined. As shown in Figure 3, both BNP and proBNP
ose-dependently stimulated intracellular cGMP produc-
ion in all 3 of these endothelial cells. However, proBNP
Figure 2 Western Blot Analysis of Immunoreactive BNP Specie
(A) Plasma samples from 5 HF patients were incubated with BNP antibody-conjuga
BNP (lane 1) and the immunoprecipitates (lanes 2 to 6) from HF individuals were
determined by the Biosite Triage point-of-care assay is indicated. (B) Recombinant
were incubated with or without deglycosylation enzymes (E) for 8 h, then subjectedas significantly less potent than BNP in stimulating sGMP production in these cells (p  0.05). The calculated
C50 values of proBNP were 6- to 8-fold higher than the
C50 values of BNP in all 3 types of endothelial cells
tudied here (Table 1), confirming that proBNP possesses
ignificantly lower activity.
In primary human aortic smooth muscle cells, proBNP
nd BNP both induced a dose-dependent increase in
GMP. However, proBNP was significantly reduced in
otency compared with BNP (Fig. 3) (p  0.05). Derived
C50 values suggest that proBNP is about 8-fold less
otent than BNP on activation of the NPRA in these
mooth muscle cells (Table 1).
To further characterize proBNP activity, we evaluated its
GMP-stimulating activity in a cell line (CHO-GCA) that
verexpresses the human NPRA receptor. Both BNP and
roBNP stimulated intracellular cGMP production in a
oncentration-dependent manner (data not shown). Con-
istent with the findings in human vascular cells, proBNP is
ignificantly less potent than BNP on stimulating intracel-
ular cGMP synthesis in CHO-GCA cells, with derived
C50 values of 111  12 nmol/l and 7  0.4 nmol/l,
espectively (p  0.05).
To determine whether the glycosylation interferes with
roBNP activity, we expressed and purified nonglycosylated
roBNP from E. coli. As shown in Figure 4, there was no
ignificant difference between recombinant mammalian
ell-derived proBNP and E. coli-expressed proBNP on
timulation of cGMP production in HAECs and CHO-
CA cells, indicating that the 2 types of recombinant
roBNP exert the same biological activity and that glyco-
lasma From HF Patients
ads for 16 h at 4°C. A control sample with 1 ng recombinant proBNP and 3 ng
ted to Western blot analysis. The BNP concentration in the patients’ plasma as
P (lanes 1 to 3) and the immunoprecipitates (lanes 4 to 6) from an HF patient
stern blot analysis. BNP  B-type naturiuretic peptide; HF  heart failure.s in P
ted be
subjec
proBN
to Weylation does not appear to affect proBNP activity.
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March 13, 2007:1071–8 Functional Heterogeneity of Circulating BNPBecause proBNP showed low cellular bioactivity, we
valuated whether proBNP modulates the cellular activity of
NP. The EC50 concentrations of each peptide, 30 nM
nd 300 nM for BNP and proBNP respectively, were
elected to treat human coronary artery endothelial cells
HCAECs) alone or in combination. Both BNP and
roBNP each gave an equivalent cGMP response, whereas
ombined they stimulated approximately 2 times greater
GMP production than each peptide alone, suggesting
NP and proBNP function in an additive fashion (data not
hown). We also tested whether NT-proBNP interferes
Figure 3 Comparison of proBNP With BNP on Stimulation of Int
cGMP Accumulation in Vascular Endothelial and Smoo
Human aortic endothelial cells (HAEC), human coronary artery endothelial cells (HC
cells (HASMC) were preincubated and treated with increasing concentrations of BN
measured. Values are mean  standard deviation. BNP  B-type naturiuretic pept
otency for Stimulation ofGMP Produc on in Primary Humanascular Cells Treated With BNP d proBNP
Table 1
Potency for Stimulation of
cGMP Production in Primary Human
Vascular Cells Treated With BNP and proBNP
Cell Type
EC50 (nmol/l)
EC50 Ratio
ProBNP/BNPBNP ProBNP
HAEC 36 3 207 49 5.8
HCAEC 58 23 436 99 7.5
HUVEC 66 12 551 82 8.3
HASMC 28 6 215 34 7.6
uman aortic endothelial cells (HAEC), coronary artery endothelial cells (HCAEC), umbilical vein
ndothelial cells (HUVEC) and arterial smooth muscle cells (HASMC), were incubated with B-typeB
atriuretic peptide (BNP) and recombinant proBNP, and the derived effective concentration (50%)
EC50) values are indicated. Data are mean  standard deviation from 3 separate experiments.ith BNP or proBNP activity. The results showed that
T-proBNP had no significant effect on BNP or proBNP-
timulated cGMP production in HCAECs (data not
hown). In other words, neither proBNP nor NT-proBNP
unctions as an effective receptor-blocking agent.
roBNP is apparently not processed to a more active
orm in the periphery (lack of detectable cell processing
f recombinant proBNP). It is possible that proBNP is
roteolytically processed to an active form in these vascular
ell assays, thereby overestimating its biological activity. The
nclusion of a protease inhibitor cocktail in the cell assay did
ot alter the activity profile of proBNP (Fig. 5). In addition,
estern blot analysis of the conditioned medium from
roBNP-treated cells could not identify any LMW-BNP
ands (data not shown). These data suggest that the
roteolysis of recombinant proBNP to an active form is not
ontributing to the activity profile of proBNP in these
ssays. However, the possibility that some processing of
roBNP to an active form does occur in these cell assays
annot be ruled out.
ubstantial cross-reactivity occurs between BNP, NT-
roBNP, and proBNP in the Triage BNP, Advia Centaur
NP, and Elecsys NT-proBNP assays. Because plasma
llular
uscle Cells
human umbilical endothelial cells (HUVEC), and human aortic smooth muscle
roBNP for 10 min. Cells were lysed, and the levels of cGMP in the lysates were
MP  cyclic guanosine monophosphate.race
th M
AEC),
P or p
ide; cGNP is a biomarker used to diagnose HF, we tested whether
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Functional Heterogeneity of Circulating BNP March 13, 2007:1071–8he Triage BNP assay, a widely used diagnostic test, could
istinguish between proBNP and BNP. Equimolar amounts of
NP or recombinant proBNP were added to normal human
lasma, and the samples were then subjected to measurement.
s shown in Figure 6A, the Triage assay recognizes BNP and
roBNP equally well, suggesting this clinical BNP assay
annot distinguish between the fully active 32-amino acid
ormone and the unprocessed prohormone with significantly
educed activity. Similar results were obtained with the Advia
entaur BNP assay, which recognized recombinant proBNP
nd BNP, with a slightly higher reactivity toward BNP (Fig.
B).
The Elecsys NT-proBNP assay, recognized recombinant
roBNP but not BNP (Fig. 7). Although there is a linear
elationship between the concentration of recombinant
roBNP in the sample and the NT-proBNP assay value
Figure 5 Protease Inhibition to Block
Processing Does Not Affect proBNP Bioactivity
Cells were preincubated with 0.1 mmol/l 3  isobutyl  1  methylzanthine
for 1 h, then treated with the indicated concentrations of proBNP in the pres-
ence or absence of a protease inhibitor cocktail for 10 min. Cells were lysed
and intracellular cGMP levels determined. BNP  B-type naturiuretic peptide;
cGMP  cyclic guanosine monophosphate.
Figure 4 Biological Activity of Glycosylated Mammalian Cell-De
Unglycosylated Bacteria-Derived proBNP on Cellular S
Cells were incubated with 0.1 mmol/l 3-isobutyl-1-methylxanthine for 1 h, treated
erichia coli for 10 min, and lysed for measurement of intracellular cGMP levels. BN
Chinese hamster ovary; GCA  guanylyl cyclase receptor A; HAEC  human aorticaR2  0.9996), the assay significantly underestimates the
olar amount of recombinant proBNP.
These results are summarized in Table 2.
iscussion
he present data offer several new insights into the hor-
onal state of HF. First, in patients with advanced HF,
uch of circulating iBNP appears to be proBNP. Second,
roBNP is 6- to 8-fold less active than BNP in our
ndothelial cell assay. Third, we found no evidence of
eripheral processing of proBNP to more active forms.
inally, we found that the currently available commercial
ssays for BNP and NT-proBNP do not clearly distinguish
etween the various circulating forms BNP, NT-proBNP,
nd proBNP.
Despite numerous studies associating plasma BNP levels
ith HF severity and clinical outcomes, little is known
bout its structure and bioactivity. It has previously been
hown that HMW forms of BNP are present in significant
mounts in HF patients and that this material is structurally
imilar if not identical to proBNP (14,15,24). Consistent
ith these reports, our Western blot analysis of plasma from
patients with advanced HF for immunoreactive BNP
aterial demonstrates significant amounts of both HMW
nd LMW species. Endogenous proBNP as well as recom-
inant, mammalian cell-derived proBNP have been shown
o be O-glycosylated (data reported here as well as reference
3). Analysis of the recombinant proBNP has shown that
lycosylation is on 7 specific sites, all within the propeptide
egion and not within the amino-terminal 32-amino acid
NP portion (23). Plasma HMW-BNP behaves similarly
o the recombinant proBNP standard when treated with
eglycosylation enzymes, confirming that endogenous
MW-BNP is a form of glycosylated proBNP. By this
riterion, recombinant mammalian cell-derived proBNP
proBNP With
sis of cGMP in HAECs and CHO-GCA Cells
creasing concentrations of proBNP expressed either from CHO cells or from Esch-
-type naturiuretic peptide; cGMP  cyclic guanosine monophosphate; CHO 
helial cells.rived
ynthe
with in
P  B
endotppears to be very reminiscent of endogenous HMW-BNP.
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March 13, 2007:1071–8 Functional Heterogeneity of Circulating BNPWe demonstrated that recombinant proBNP has reduced
6- to 8-fold) biological activity compared with the 32-
mino acid BNP peptide on both endothelial and vascular
mooth muscle cells. Recombinant proBNP also has re-
uced potency for activating human NPRA expressed re-
ombinantly in mammalian cells, suggesting that the results
oted in primary human endothelial cells and vascular
mooth muscle cells are NPRA mediated. The vasculature is
key target organ for BNP physiology, and both endothelial
ells and smooth muscle cells express the hormone’s biolog-
cal receptor, NPRA (19). B-Type natriuretic peptide acts
irectly on endothelial cells to reduce endothelin-1 produc-
ion as well as modulate fluid permeability (1). Acting on
ascular smooth muscle, BNP has been shown to be a
asodilator (25). The cellular effects of proBNP and BNP
escribed here are thus a critical part of the physiology of
his hormone. These data suggest that the unprocessed
Figure 6 Triage BNP and Advia Centaur BNP Tests Detect Both
BNP and recombinant (mammalian cell-derived) proBNP were added to normal hum
plasma BNP or proBNP were measured by Triage BNP test (A) or Advia Centaur te
Figure 7 Elecsys 2010 proBNP Test Detects proBNP
BNP and recombinant (Mammalian cell-derived) proBNP added to normal
human plasma. The levels of plasma BNP or proBNP were measured by theBormone has significantly reduced activity compared with
he mature BNP peptide.
The mechanism(s) leading to significantly increased
mounts of circulating proBNP in the setting of HF is
nknown. We explored this by inclusion of protease inhib-
tors in our cell-line cGMP assay. Our findings support the
ypothesis that physiologically important peripheral conver-
ion of proBNP to active BNP does not occur. Activation of
he gene’s promoter in HF leads to a marked increase in
roBNP expression by cardiac myocytes (6,8,26). The
ncreased production of proBNP may overwhelm the ability
f cardiac myocytes to process it to the mature 32-amino
cid peptide, thereby resulting in the release of significant
mounts of proBNP rather than BNP. Alternatively, the
rocessing and/or metabolism of proBNP in the circulation
ay be reduced or the metabolism of BNP may be in-
reased. B-type natriuretic peptide is metabolized predom-
nantly by natriuretic peptide clearance receptor and neutral
ndopeptidase cleavage (27–29). Whether proBNP shares
etabolic pathways similar to those of BNP remains to be
etermined. Further studies on the processing and metab-
lism of proBNP should advance our understanding of
olecular forms of BNP circulating in HF.
Finally, we addressed the ability of commercially available
ssays to distinguish the different BNP forms circulating in
atients with advanced HF. Recombinant mammalian cell-
erived proBNP is as effectively detected by the Triage BNP
ssay kit as BNP. The available literature suggests that this
and proBNP
sma. The levels of
BNP  B-type naturiuretic peptide.
ross-Reactivity of BNP Forms in 3 Assays
Table 2 Cross-Reactivity of BNP Forms in 3 Assays
Assay
BNP Forms Detected
BNP NT-proBNP proBNP
Triage Yes No Yes
Advia Centaur Yes No Yes
ElecSys No Yes YesBNP
an pla
st (B).NT-proBNP test. BNP  B-type naturiuretic peptide.
NP  B-type natriuretic peptide.
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tructure of the BNP peptide and a detection antibody that
ecognizes the amino terminus of BNP (30). Thus, one
ould predict that this assay should detect proBNP. These
esults were confirmed by the Advia Centaur BNP test,
nother widely used BNP diagnostic assay. The Elecsys
T-proBNP assay also detected recombinant proBNP;
owever, it significantly underestimated the amount of
rotein present. It is possible that the glycosylation of the
roBNP protein in the NT region (amino acids 1 to 76)
nterferes with the assay. Because endogenous proBNP is
lso glycosylated, it is anticipated that values generated with
his assay may not reflect actual blood levels (data here and
eference 23).
In summary, the present data offer at least a partial
xplanation of why HF patients with high levels of immu-
oreactive plasma BNP may still suffer from severe symp-
oms, e.g., congestion and edema, in that BNP forms with
ittle physiologic activity, such as proBNP, seem to consti-
ute much of the circulating iBNP in advanced HF.
hether the levels of active 32-amino acid BNP rise
roportionately, as suggested by Giuliani et al. (16), or are
elatively deficient, remains a topic for further study. Addi-
ional mechanisms limiting the activity of BNP in the HF
etting may include activation of cGMP phosphodiesterases
r down-modulation of NPRA. Further work in this area
ill better define the structure and activity of endogenous
atriuretic peptides in the setting of heart disease.
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